113
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Clinical Utility of Central and Peripheral Airway Nitric Oxide in Aging Patients with Stable and Acute Exacerbated Chronic Obstructive Pulmonary Disease

, , , , , , , , , , , , , , & show all
Pages 571-580 | Published online: 23 Feb 2021

References

  • Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: impact, measurement and mechanisms. Respirology. 2015;20:1160–1171. doi:10.1111/resp.12642
  • Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27. doi:10.1016/j.jaci.2016.05.011
  • Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):758–766. doi:10.1164/rccm.201408-1458OC
  • Oishi K, Matsunaga K, Shirai T, et al. Role of type2 inflammatory biomarkers in chronic obstructive pulmonary disease. J Clin Med. 2020;9(8):2670. doi:10.3390/jcm9082670
  • Beg MF, Alzoghaibi MA, Abba AA, et al. Exhaled nitric oxide in stable chronic obstructive pulmonary disease. Ann Thorac Med. 2009;4:65–70. doi:10.4103/1817-1737.44649
  • Bazeghi N, Gerds TA, Budtz-Jorgensen E, et al. Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD. Respir Med. 2011;105:1338–1344. doi:10.1016/j.rmed.2011.03.015
  • Chou KT, Su KC, Huang SF, et al. Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD. Lung. 2014;192:499–504. doi:10.1007/s00408-014-9591-8
  • Malerba M, Radaeli A, Olivini A, et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int. 2014;2014:271918. doi:10.1155/2014/271918
  • Karampitsakos T, Gourgoulianis KI. Asthma-COPD overlap syndrome (ACOS): single disease entity or not? Could exhaled nitric oxide be a useful biomarker for the differentiation of ACOS, asthma and COPD? Med Hypotheses. 2016;91:20–23. doi:10.1016/j.mehy.2016.04.008
  • Alcazar-Navarrete B, Ruiz Rodriguez O, Conde Baena P, et al. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J. 2018;51:1701457. doi:10.1183/13993003.01457-2017
  • Horvath I, Barnes PJ, Loukides S, et al. A European respiratory society technical standard: exhaled biomarkers in lung disease. Eur Respir J. 2017;49:1600965. doi:10.1183/13993003.00965-2016
  • Hogman M, Holmkvist T, Wegener T, et al. Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis. Respir Med. 2002;96:24–30. doi:10.1053/rmed.2001.1204
  • Brindicci C, Ito K, Resta O, et al. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J. 2005;26:52–59. doi:10.1183/09031936.04.00125304
  • Williamson PA, Clearie K, Menzies D, et al. Assessment of small-airways disease using alveolar nitric oxide and impulse oscillometry in asthma and COPD. Lung. 2011;189:121–129. doi:10.1007/s00408-010-9275-y
  • Hirano T, Matsunaga K, Sugiura H, et al. Relationship between alveolar nitric oxide concentration in exhaled air and small airway function in COPD. J Breath Res. 2013;7:046002. doi:10.1088/1752-7155/7/4/046002
  • Lazar Z, Kelemen A, Galffy G, et al. Central and peripheral airway nitric oxide in patients with stable and exacerbated chronic obstructive pulmonary disease. J Breath Res. 2018;12:036017. doi:10.1088/1752-7163/aac10a
  • Short PM, Williamson PA, Lipworth BJ. Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD. Lung. 2012;190:395–401. doi:10.1007/s00408-012-9378-8
  • Gelb AF, Flynn Taylor C, Krishnan A, et al. Central and peripheral airway sites of nitric oxide gas exchange in COPD. Chest. 2010;137:575–584. doi:10.1378/chest.09-1522
  • Paredi P, Kharitonov SA, Meah S, et al. A novel approach to partition central and peripheral airway nitric oxide. Chest. 2014;145:113–119. doi:10.1378/chest.13-0843
  • Delclaux C, Mahut B, Zerah-Lancner F, et al. Increased nitric oxide output from alveolar origin during liver cirrhosis versus bronchial source during asthma. Am J Respir Crit Care Med. 2002;165:332–337. doi:10.1164/ajrccm.165.3.2107017
  • Gupta S, Zamel N, Faughnan ME. Alveolar exhaled nitric oxide is elevated in hereditary hemorrhagic telangiectasia. Lung. 2009;187:43–49. doi:10.1007/s00408-008-9125-3
  • Lam Shin Cheung J, Naimi M, Sykes J, et al. A role for alveolar exhaled nitric oxide measurement in the diagnosis of hepatopulmonary syndrome. J Clin Gastroenterol. 2020;54:278–283. doi:10.1097/MCG.0000000000001246
  • American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912–930. doi:10.1164/rccm.200406-710ST
  • Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol. 1998;85:653–666. doi:10.1152/jappl.1998.85.2.653
  • Hogman M, Merilainen P. Extended NO analysis in asthma. J Breath Res. 2007;1:024001. doi:10.1088/1752-7155/1/2/024001
  • Hogman M. Extended NO analysis in health and disease. J Breath Res. 2012;6:047103. doi:10.1088/1752-7155/6/4/047103
  • Lehouck A, Carremans C, De Bent K, et al. Alveolar and bronchial exhaled nitric oxide in chr onic obstructive pulmonary disease. Respir Med. 2010;104:1020–1026. doi:10.1016/j.rmed.2010.01.001
  • Sugiura H, Ichinose M. Nitrative stress in inflammatory lung diseases. Nitric Oxide. 2011;25:138–144. doi:10.1016/j.niox.2011.03.079
  • Pavord ID, Jones PW, Burgel PR, et al. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:21–30. doi:10.2147/COPD.S85978
  • Zong F, Zuo XR, Wang Q, et al. Iptakalim rescues human pulmonary artery endothelial cells from hypoxia-induced nitric oxide system dysfunction. Exp Ther Med. 2012;3:535–539. doi:10.3892/etm.2011.414
  • Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–1121. doi:10.1164/rccm.200506-859OC
  • Lu Z, Huang W, Wang L, et al. Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:2695–2705. doi:10.2147/COPD.S165780
  • Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–615. doi:10.1164/rccm.9120-11ST
  • Yamaji Y, Oishi K, Hamada K, et al. Detection of type2 biomarkers for response in COPD. J Breath Res. 2020;14:026007. doi:10.1088/1752-7163/ab71a4
  • Hogman M, Ludviksdottir D, Anderson SD, et al. Inhaled mannitol shifts exhaled nitric oxide in opposite directions in asthmatics and healthy subjects. Respir Physiol. 2001;124:141–150. doi:10.1016/S0034-5687(00)00195-X
  • Lehtimaki L, Kankaanranta H, Saarelainen S, et al. Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. Am J Respir Crit Care Med. 2001;163:1557–1561. doi:10.1164/ajrccm.163.7.2010171
  • Lehtimaki L, Kankaanranta H, Saarelainen S, et al. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur Respir J. 2002;20:841–845. doi:10.1183/09031936.02.00202002
  • Tiev KP, Cabane J, Aubourg F, et al. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J. 2007;30:26–30. doi:10.1183/09031936.00129806
  • Hua-Huy T, Tiev KP, Chereau C, et al. Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in patients with systemic sclerosis. J Rheumatol. 2010;37:1680–1687. doi:10.3899/jrheum.090915
  • Wuttge DM, Bozovic G, Hesselstrand R, et al. Increased alveolar nitric oxide in early systemic sclerosis. Clin Exp Rheumatol. 2010;28:S5–9.
  • Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53:1900164. doi:10.1183/13993003.00164-2019
  • Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease: a network analysis. Am J Respir Crit Care Med. 2020;201:1078–1085. doi:10.1164/rccm.201908-1550OC